

FINANCIAL EXPRESS

ARVEE LABORATORIES (INDIA) LIMITED

Registered Address: 403, Entice, Nr. Jayantilal Park BRTS, Iskon Bopal Road, Ambli, Ahmedabad, Gujarat 380058
 Telephone: +91-2717-430479 / +91-2717-410819, Website : www.arveelabs.com
 CIN : L24231GJ2012PLC068778 Email : compliance@arveelabs.com

EXTRACT OF THE STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON DECEMBER 31, 2021 (₹ in lakhs except per share data)

Sr. No.	Particular	Quarter ended			Nine Month ended		Year ended
		31-12-2021 (Un Audited)	30-09-2021 (Un Audited)	31-12-2020 (Un Audited)	31-12-2021 (Un Audited)	31-12-2020 (Un Audited)	31-03-2021 (Audited)
1.	Total Revenue from operations	790.06	1069.98	1994.48	2766.23	3818.53	4737.50
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	66.73	103.84	204.45	241.18	301.26	364.14
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	66.73	103.84	204.45	241.18	301.26	364.14
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	53.39	72.59	152.99	178.82	224.30	267.74
5.	Total Comprehensive Income for the period	53.39	72.59	152.99	178.82	224.30	267.74
6.	Paid up Equity Share Capital (Face value of Rs.10/- each)	1102.00	1102.00	1102.00	1102.00	1102.00	1102.00
7.	Other Equity excluding revaluation reserves						1041.82
8.	Earnings Per Share (of Rs.10/- each) (Not Annualised) (for continuing & discontinued operations)						
	a) Basic	0.48	0.66	1.39	1.62	4.07	2.43
	b) Diluted	0.48	0.66	1.39	1.62	4.07	2.43

Notes:

- The above is an extract of the detailed format of Financial Results for the quarter ended December 31, 2021 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the said Results are available on the Stock Exchange website (www.nseindia.com) and on the Company's website (www.arveelabs.com).
- In line with Ind AS - 108 Operating Segments and basis of the review of operations being done by the Senior Management, the operations of the Company fall under the Chemicals business which is considered to be the only reportable segment by the management.

For, Arvee Laboratories (India) Limited
 S/d
SHALIN SUDHAKARBHAI PATEL
 Chairman & Managing Director

Place : Ahmedabad
 Date : February 08, 2022



Regd. Office: Baroda - Godhra Highway, Kalol, District Panchmahal, Pin Code - 389 330, Gujarat. • **Tel:** 02676 - 270600 • **Fax:** 02676 -235524
Website: www.setcoauto.com • **Email:** investor.relations@setcoauto.com
CIN.: U35100GJ2010PTC062770

Extract of Standalone Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2021

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-Dec-21 (Unaudited)	30-Sep-21 (Unaudited)	31-Dec-20 (Unaudited)	31-Dec-21 (Unaudited)	31-Dec-20 (Unaudited)	31-Mar-21 (Audited)
1	Total Income from Operations	10,254	2,283	-	12,537	-	-
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(3,132)	(1,954)	-	(5,086)	-	-
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(3,132)	(12,730)	-	(15,862)	-	-
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(3,132)	(12,730)	-	(15,862)	-	-
5	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(3,132)	(12,730)	-	(15,862)	-	-
6	Paid-up Equity Share Capital (F.V. of Rs. 10/- each)	87	87	-	87	-	1
7	Reserves (excluding Revaluation Reserve) *	(24,127)	(20,995)	-	(24,127)	-	(3)
8	Securities Premium Account	4,962	4,962	-	4,962	-	-
9	Net worth	(24,040)	(20,907)	-	(24,040)	-	(2)
10	Paid up Debt Capital/ Outstanding Debt	56,522	56,522	-	56,522	-	-
11	Outstanding Redeemable Preference Shares	-	-	-	-	-	-
12	Debt Equity Ratio	(2.60)	(2.85)	-	(2.60)	-	(0.47)
13	Earnings Per Share (F.V. of ₹ 10/- each)						
	Basic	(549.11)	(3,046.60)	-	(2,780.86)	-	(1.50)
	Diluted	(472.74)	(2,851.10)	-	(2,394.07)	-	(1.50)
14	Capital Redemption Reserve	-	-	-	-	-	-
15	Debtenture Redemption Reserve	-	-	-	-	-	-
16	Debt Service Coverage Ratio	0.004	(1.06)	-	(0.27)	-	-

PRISE LIMITED

PLC018943
C. G. Road, Navrangpura, Ahmedabad - 380 009

for the Quarter ended 31/12/2021

(Rs. In Lakhs except EPS)

Quarter ending on 31.12.2021	Year to Date Figures 31.12.2021	Corresponding Three Months Ended in the Previous Year 31.12.2020
0.52	0.95	0.56
0.01	0.01	0.05
0.01	0.01	0.05
0.01	0.01	0.05
0.01	0.01	0.05
385.04	385.04	385.04
10/-	10/-	10/-
0.00	0.00	0.00

of Quarterly Financial Results filed
33 of the SEBI (LODR) Regulations,
al Results are available on the Stock

For, **Aryavan Enterprise Limited**

SD/-
Jitendrakumar Malviya
Managing Director
DIN: 08015437

ARVEE LABORATORIES (INDIA) LIMITED

Registered Address: 403, Entice, Nr. Jayantilal Park BRTS, Iskon Bopal Road, Ambli, Ahmedabad, Gujarat 380058
Telephone: +91-2717-430479 / +91-2717-410819, Website: www.arveelabs.com
CIN : L24231GJ2012PLC068778 Email : compliance@arveelabs.com

EXTRACT OF THE STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON DECEMBER 31, 2021 (₹ in lakhs except per share data)

Sr. No.	Particular	Quarter ended			Nine Month ended		Year ended
		31-12-2021 (Un Audited)	30-09-2021 (Un Audited)	31-12-2020 (Un Audited)	31-12-2021 (Un Audited)	31-12-2020 (Un Audited)	31-03-2021 (Audited)
1.	Total Revenue from operations	790.06	1069.98	1994.48	2766.23	3818.53	4737.50
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	66.73	103.84	204.45	241.18	301.26	364.14
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	66.73	103.84	204.45	241.18	301.26	364.14
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	53.39	72.59	152.99	178.82	224.30	267.74
5.	Total Comprehensive Income for the period	53.39	72.59	152.99	178.82	224.30	267.74
6.	Paid up Equity Share Capital (Face value of Rs.10/- each)	1102.00	1102.00	1102.00	1102.00	1102.00	1102.00
7.	Other Equity excluding revaluation reserves						
8.	Earnings Per Share (of Rs.10/- each) (Not Annualised) (for continuing & discontinued operations)						
	a) Basic	0.48	0.66	1.39	1.62	4.07	2.43
	b) Diluted	0.48	0.66	1.39	1.62	4.07	2.43

Notes:

- The above is an extract of the detailed format of Financial Results for the quarter ended December 31, 2021 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the said Results are available on the Stock Exchange website (www.nseindia.com) and on the Company's website (www.arveelabs.com).
- In line with Ind AS - 108 Operating Segments and basis of the review of operations being done by the Senior Management, the operations of the Company fall under the Chemicals business which is considered to be the only reportable segment by the management.

For, **Arvee Laboratories (India) Limited**
S/d

SHALIN SUDHAKARBHAI PATEL
Chairman & Managing Director

Place : Ahmedabad

Date : February 08, 2022

This is only an advertisement for information purposes and is not a prospectus announcement.



MadhavbaugTM
Multidisciplinary Cardiac Care Clinics & Hospitals

SANE AYURVED LABORATORIES LIMITED

Corporate Identification Number: U73100PN1999PLC013509

is a private limited company under the Companies Act, 1956 pursuant to a certificate of incorporation issued by the Registrar of Companies, Pune dated April 6, 1999 with the name 'Vaidya Sane Ayurved Laboratories Private' converted into a public limited company and the name of our Company was changed to 'Vaidya Sane Ayurved Laboratories Limited' by a special resolution passed on November 19, 2021. A fresh Certificate of Incorporation in November 25, 2021 by the Registrar of Companies, Pune. For further details of our Company, see "General Information" and "History and Certain Other Corporate Matters" on pages 41 and 93, respectively of the

m Bhawan, Shukrawar Peth, Pune - 411002, Maharashtra, India; Office Address where books of account and papers are maintained: 201 B, Bhoomi Velocity, Road No. 23, Above ICICI Bank, - 400604, Maharashtra, India; Tel: +91 7738070019; Website: www.madhavbaug.org; E-mail: cs@madhavbaug.com; Contact Person: Abhishek Ajay Deshpande, Company Secretary and

PROMOTER OF THE COMPANY: DR. ROHIT MADHAV SANE

THE ISSUE

EQUITY SHARES OF FACE VALUE OF ₹ 10.00 EACH OF VAIDYA SANE AYURVED LABORATORIES LIMITED ("OUR COMPANY" OR "THE ISSUER") ₹ 73.00 PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ 63.00 PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO ₹ 2,022.98 THE ISSUE, 1,40,800 EQUITY SHARES AGGREGATING TO ₹ 102.78 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 26,30,400 EQUITY SHARES OF FACE VALUE OF PRICE OF ₹ 73.00 PER EQUITY SHARE AGGREGATING TO ₹ 1920.19 LAKHS IS HERINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND TITUTE 26.36% AND 25.02%, RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, ON PAGE 179 OF THE PROSPECTUS.